Abnormal Patterns of Immunoglobulin Heavy Chain Gene DNA Fingerprinting During Chronic Phase Chronic Myeloid Leukemia

Using IgH DNA fingerprinting we have previously demonstrated clonal immunoglobulin heavy chain (IgH) gene rearrangements during chronic phase (CP) chronic myeloid leukemia (CML) in patients destined to develop lymphoid blast crisis (L-BC). In view of this we decided to follow a cohort of CP CML pati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia & lymphoma 1999, Vol.32 (3-4), p.299-307
Hauptverfasser: Spencer, Andrew, Szydlo, Richard, Grand, Francis H., Goldman, John M., Melo, Junia V.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 307
container_issue 3-4
container_start_page 299
container_title Leukemia & lymphoma
container_volume 32
creator Spencer, Andrew
Szydlo, Richard
Grand, Francis H.
Goldman, John M.
Melo, Junia V.
description Using IgH DNA fingerprinting we have previously demonstrated clonal immunoglobulin heavy chain (IgH) gene rearrangements during chronic phase (CP) chronic myeloid leukemia (CML) in patients destined to develop lymphoid blast crisis (L-BC). In view of this we decided to follow a cohort of CP CML patients to determine the frequency with which abnormal IgH fingerprints are found and their relationship, if any, to treatment regimen. Thirty three, initially CP, CML patients were studied on 111 occasions over a 16 month period using consensus PCR amplification of the third complementarity determining region (CDR3) of the IgH gene and high resolution polyacrylamide gel electrophoresis (IgH DNA fingerprinting). Of these 33 patients, thirteen received interferon-alpha (IFN) containing regimens and 15 non-IFN containing regimens throughout the study period. Five patients received variable therapy. During the period of observation 7 patients experienced disease progression: 5 accelerated phase, 1 L-BC and 1 myeloid blast crisis (M-BC). Abnormal IgH fingerprints were seen in 29 of the 111 (26%) specimens analysed. The 28 patients who received uniform therapy (IFN or non-IFN) over the 16 months were classified as "normal" (n=18, normal pattern on all occasions) or "abnormal" (n=10, abnormal on 1 or more occasions). Analysis by patient group (normal vs abnormal) showed that fingerprint abnormalities were associated with an elevated peripheral blood lymphocyte count (p=0.0001) but not with changes in the total white cell count. Comparison of the IFN vs non-IFN groups showed the former all had normal patterns whereas 10 of 15 non-IFN therapy patients were abnormal (p=0.00023). The peripheral blood lymphocyte counts in the normal vs abnormal patients within the non-IFN group were not significantly different. The patient who developed L-BC demonstrated a persistent IgH fingerprint pattern abnormality from 7 months prior to the diagnosis of L-BC. The M-BC patient had a normal pattern at all times. We conclude that: (1) abnormal IgH fingerprints are found in a significant number of CP CML patients; (2) in this cohort the use of IFN was associated with normal CP CML IgH fingerprints, and (3) detection of abnormal IgH fingerprints may be highly predictive for the lineage of impending blast crisis.
doi_str_mv 10.3109/10428199909167390
format Article
fullrecord <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_informahealthcare_journals_10_3109_10428199909167390</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17218381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-8c6354ba209914e4deae8e3684852fbd16d74fd777f32124dabc38393708e8763</originalsourceid><addsrcrecordid>eNqFkUtv1DAUhS1ERUvhB7BBXrEL9WtiW7AZTelDmpYuYB05yU3j4tjFjkHz73E0FSpC0NU9lr5z5HsPQm8oec8p0SeUCKao1ppoWkuuyTN0RAnTFROEP1-0YFUBxCF6mdIdIWSla_YCHVJCuCRMHqG8bn2Ik3H4xswzRJ9wGPDlNGUfbl1os7MeX4D5scOb0RR9Dh7w6fUan1l_C_E-Wj8XhU9zXMZmjMHbDt-MJsHv19UOXLA93kL-BpM1r9DBYFyC1w_zGH09-_Rlc1FtP59fbtbbqhOcz5Xqar4SrWFEaypA9GBAAa-VUCs2tD2teymGXko5cEaZ6E3bccV12U2BkjU_Ru_2ufcxfM-Q5mayqQPnjIeQU1PrchCu9ZMglYwqrmgB6R7sYkgpwtCUC0wm7hpKmqWU5q9SiuftQ3huJ-gfOfYtFODjHrB-WMr4GaLrm9nsXIhDNL6zacn-d_6HP-wjGDePnYnQ3IUcfbnwf373CxdZrGY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17218381</pqid></control><display><type>article</type><title>Abnormal Patterns of Immunoglobulin Heavy Chain Gene DNA Fingerprinting During Chronic Phase Chronic Myeloid Leukemia</title><source>MEDLINE</source><source>Taylor &amp; Francis Medical Library - CRKN</source><source>Taylor &amp; Francis Journals Complete</source><creator>Spencer, Andrew ; Szydlo, Richard ; Grand, Francis H. ; Goldman, John M. ; Melo, Junia V.</creator><creatorcontrib>Spencer, Andrew ; Szydlo, Richard ; Grand, Francis H. ; Goldman, John M. ; Melo, Junia V.</creatorcontrib><description>Using IgH DNA fingerprinting we have previously demonstrated clonal immunoglobulin heavy chain (IgH) gene rearrangements during chronic phase (CP) chronic myeloid leukemia (CML) in patients destined to develop lymphoid blast crisis (L-BC). In view of this we decided to follow a cohort of CP CML patients to determine the frequency with which abnormal IgH fingerprints are found and their relationship, if any, to treatment regimen. Thirty three, initially CP, CML patients were studied on 111 occasions over a 16 month period using consensus PCR amplification of the third complementarity determining region (CDR3) of the IgH gene and high resolution polyacrylamide gel electrophoresis (IgH DNA fingerprinting). Of these 33 patients, thirteen received interferon-alpha (IFN) containing regimens and 15 non-IFN containing regimens throughout the study period. Five patients received variable therapy. During the period of observation 7 patients experienced disease progression: 5 accelerated phase, 1 L-BC and 1 myeloid blast crisis (M-BC). Abnormal IgH fingerprints were seen in 29 of the 111 (26%) specimens analysed. The 28 patients who received uniform therapy (IFN or non-IFN) over the 16 months were classified as "normal" (n=18, normal pattern on all occasions) or "abnormal" (n=10, abnormal on 1 or more occasions). Analysis by patient group (normal vs abnormal) showed that fingerprint abnormalities were associated with an elevated peripheral blood lymphocyte count (p=0.0001) but not with changes in the total white cell count. Comparison of the IFN vs non-IFN groups showed the former all had normal patterns whereas 10 of 15 non-IFN therapy patients were abnormal (p=0.00023). The peripheral blood lymphocyte counts in the normal vs abnormal patients within the non-IFN group were not significantly different. The patient who developed L-BC demonstrated a persistent IgH fingerprint pattern abnormality from 7 months prior to the diagnosis of L-BC. The M-BC patient had a normal pattern at all times. We conclude that: (1) abnormal IgH fingerprints are found in a significant number of CP CML patients; (2) in this cohort the use of IFN was associated with normal CP CML IgH fingerprints, and (3) detection of abnormal IgH fingerprints may be highly predictive for the lineage of impending blast crisis.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.3109/10428199909167390</identifier><identifier>PMID: 10037027</identifier><language>eng</language><publisher>United States: Informa UK Ltd</publisher><subject>blast crisis ; chronic myeloid leukaemia ; chronic phase ; DNA Fingerprinting ; Genes, Immunoglobulin ; Humans ; IgH DNA fingerprinting ; immunoglobin heavy chain gene ; Immunoglobulin Heavy Chains - genetics ; interferon ; Leukemia, Myeloid, Chronic-Phase - genetics ; Leukemia, Myeloid, Chronic-Phase - immunology ; Leukemia, Myeloid, Chronic-Phase - therapy</subject><ispartof>Leukemia &amp; lymphoma, 1999, Vol.32 (3-4), p.299-307</ispartof><rights>1999 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-8c6354ba209914e4deae8e3684852fbd16d74fd777f32124dabc38393708e8763</citedby><cites>FETCH-LOGICAL-c433t-8c6354ba209914e4deae8e3684852fbd16d74fd777f32124dabc38393708e8763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/10428199909167390$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/10428199909167390$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,4009,27902,27903,27904,59623,59729,60412,60518,61197,61232,61378,61413</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10037027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Spencer, Andrew</creatorcontrib><creatorcontrib>Szydlo, Richard</creatorcontrib><creatorcontrib>Grand, Francis H.</creatorcontrib><creatorcontrib>Goldman, John M.</creatorcontrib><creatorcontrib>Melo, Junia V.</creatorcontrib><title>Abnormal Patterns of Immunoglobulin Heavy Chain Gene DNA Fingerprinting During Chronic Phase Chronic Myeloid Leukemia</title><title>Leukemia &amp; lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>Using IgH DNA fingerprinting we have previously demonstrated clonal immunoglobulin heavy chain (IgH) gene rearrangements during chronic phase (CP) chronic myeloid leukemia (CML) in patients destined to develop lymphoid blast crisis (L-BC). In view of this we decided to follow a cohort of CP CML patients to determine the frequency with which abnormal IgH fingerprints are found and their relationship, if any, to treatment regimen. Thirty three, initially CP, CML patients were studied on 111 occasions over a 16 month period using consensus PCR amplification of the third complementarity determining region (CDR3) of the IgH gene and high resolution polyacrylamide gel electrophoresis (IgH DNA fingerprinting). Of these 33 patients, thirteen received interferon-alpha (IFN) containing regimens and 15 non-IFN containing regimens throughout the study period. Five patients received variable therapy. During the period of observation 7 patients experienced disease progression: 5 accelerated phase, 1 L-BC and 1 myeloid blast crisis (M-BC). Abnormal IgH fingerprints were seen in 29 of the 111 (26%) specimens analysed. The 28 patients who received uniform therapy (IFN or non-IFN) over the 16 months were classified as "normal" (n=18, normal pattern on all occasions) or "abnormal" (n=10, abnormal on 1 or more occasions). Analysis by patient group (normal vs abnormal) showed that fingerprint abnormalities were associated with an elevated peripheral blood lymphocyte count (p=0.0001) but not with changes in the total white cell count. Comparison of the IFN vs non-IFN groups showed the former all had normal patterns whereas 10 of 15 non-IFN therapy patients were abnormal (p=0.00023). The peripheral blood lymphocyte counts in the normal vs abnormal patients within the non-IFN group were not significantly different. The patient who developed L-BC demonstrated a persistent IgH fingerprint pattern abnormality from 7 months prior to the diagnosis of L-BC. The M-BC patient had a normal pattern at all times. We conclude that: (1) abnormal IgH fingerprints are found in a significant number of CP CML patients; (2) in this cohort the use of IFN was associated with normal CP CML IgH fingerprints, and (3) detection of abnormal IgH fingerprints may be highly predictive for the lineage of impending blast crisis.</description><subject>blast crisis</subject><subject>chronic myeloid leukaemia</subject><subject>chronic phase</subject><subject>DNA Fingerprinting</subject><subject>Genes, Immunoglobulin</subject><subject>Humans</subject><subject>IgH DNA fingerprinting</subject><subject>immunoglobin heavy chain gene</subject><subject>Immunoglobulin Heavy Chains - genetics</subject><subject>interferon</subject><subject>Leukemia, Myeloid, Chronic-Phase - genetics</subject><subject>Leukemia, Myeloid, Chronic-Phase - immunology</subject><subject>Leukemia, Myeloid, Chronic-Phase - therapy</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1DAUhS1ERUvhB7BBXrEL9WtiW7AZTelDmpYuYB05yU3j4tjFjkHz73E0FSpC0NU9lr5z5HsPQm8oec8p0SeUCKao1ppoWkuuyTN0RAnTFROEP1-0YFUBxCF6mdIdIWSla_YCHVJCuCRMHqG8bn2Ik3H4xswzRJ9wGPDlNGUfbl1os7MeX4D5scOb0RR9Dh7w6fUan1l_C_E-Wj8XhU9zXMZmjMHbDt-MJsHv19UOXLA93kL-BpM1r9DBYFyC1w_zGH09-_Rlc1FtP59fbtbbqhOcz5Xqar4SrWFEaypA9GBAAa-VUCs2tD2teymGXko5cEaZ6E3bccV12U2BkjU_Ru_2ufcxfM-Q5mayqQPnjIeQU1PrchCu9ZMglYwqrmgB6R7sYkgpwtCUC0wm7hpKmqWU5q9SiuftQ3huJ-gfOfYtFODjHrB-WMr4GaLrm9nsXIhDNL6zacn-d_6HP-wjGDePnYnQ3IUcfbnwf373CxdZrGY</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>Spencer, Andrew</creator><creator>Szydlo, Richard</creator><creator>Grand, Francis H.</creator><creator>Goldman, John M.</creator><creator>Melo, Junia V.</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>1999</creationdate><title>Abnormal Patterns of Immunoglobulin Heavy Chain Gene DNA Fingerprinting During Chronic Phase Chronic Myeloid Leukemia</title><author>Spencer, Andrew ; Szydlo, Richard ; Grand, Francis H. ; Goldman, John M. ; Melo, Junia V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-8c6354ba209914e4deae8e3684852fbd16d74fd777f32124dabc38393708e8763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>blast crisis</topic><topic>chronic myeloid leukaemia</topic><topic>chronic phase</topic><topic>DNA Fingerprinting</topic><topic>Genes, Immunoglobulin</topic><topic>Humans</topic><topic>IgH DNA fingerprinting</topic><topic>immunoglobin heavy chain gene</topic><topic>Immunoglobulin Heavy Chains - genetics</topic><topic>interferon</topic><topic>Leukemia, Myeloid, Chronic-Phase - genetics</topic><topic>Leukemia, Myeloid, Chronic-Phase - immunology</topic><topic>Leukemia, Myeloid, Chronic-Phase - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spencer, Andrew</creatorcontrib><creatorcontrib>Szydlo, Richard</creatorcontrib><creatorcontrib>Grand, Francis H.</creatorcontrib><creatorcontrib>Goldman, John M.</creatorcontrib><creatorcontrib>Melo, Junia V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia &amp; lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spencer, Andrew</au><au>Szydlo, Richard</au><au>Grand, Francis H.</au><au>Goldman, John M.</au><au>Melo, Junia V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abnormal Patterns of Immunoglobulin Heavy Chain Gene DNA Fingerprinting During Chronic Phase Chronic Myeloid Leukemia</atitle><jtitle>Leukemia &amp; lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>1999</date><risdate>1999</risdate><volume>32</volume><issue>3-4</issue><spage>299</spage><epage>307</epage><pages>299-307</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>Using IgH DNA fingerprinting we have previously demonstrated clonal immunoglobulin heavy chain (IgH) gene rearrangements during chronic phase (CP) chronic myeloid leukemia (CML) in patients destined to develop lymphoid blast crisis (L-BC). In view of this we decided to follow a cohort of CP CML patients to determine the frequency with which abnormal IgH fingerprints are found and their relationship, if any, to treatment regimen. Thirty three, initially CP, CML patients were studied on 111 occasions over a 16 month period using consensus PCR amplification of the third complementarity determining region (CDR3) of the IgH gene and high resolution polyacrylamide gel electrophoresis (IgH DNA fingerprinting). Of these 33 patients, thirteen received interferon-alpha (IFN) containing regimens and 15 non-IFN containing regimens throughout the study period. Five patients received variable therapy. During the period of observation 7 patients experienced disease progression: 5 accelerated phase, 1 L-BC and 1 myeloid blast crisis (M-BC). Abnormal IgH fingerprints were seen in 29 of the 111 (26%) specimens analysed. The 28 patients who received uniform therapy (IFN or non-IFN) over the 16 months were classified as "normal" (n=18, normal pattern on all occasions) or "abnormal" (n=10, abnormal on 1 or more occasions). Analysis by patient group (normal vs abnormal) showed that fingerprint abnormalities were associated with an elevated peripheral blood lymphocyte count (p=0.0001) but not with changes in the total white cell count. Comparison of the IFN vs non-IFN groups showed the former all had normal patterns whereas 10 of 15 non-IFN therapy patients were abnormal (p=0.00023). The peripheral blood lymphocyte counts in the normal vs abnormal patients within the non-IFN group were not significantly different. The patient who developed L-BC demonstrated a persistent IgH fingerprint pattern abnormality from 7 months prior to the diagnosis of L-BC. The M-BC patient had a normal pattern at all times. We conclude that: (1) abnormal IgH fingerprints are found in a significant number of CP CML patients; (2) in this cohort the use of IFN was associated with normal CP CML IgH fingerprints, and (3) detection of abnormal IgH fingerprints may be highly predictive for the lineage of impending blast crisis.</abstract><cop>United States</cop><pub>Informa UK Ltd</pub><pmid>10037027</pmid><doi>10.3109/10428199909167390</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1042-8194
ispartof Leukemia & lymphoma, 1999, Vol.32 (3-4), p.299-307
issn 1042-8194
1029-2403
language eng
recordid cdi_informahealthcare_journals_10_3109_10428199909167390
source MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete
subjects blast crisis
chronic myeloid leukaemia
chronic phase
DNA Fingerprinting
Genes, Immunoglobulin
Humans
IgH DNA fingerprinting
immunoglobin heavy chain gene
Immunoglobulin Heavy Chains - genetics
interferon
Leukemia, Myeloid, Chronic-Phase - genetics
Leukemia, Myeloid, Chronic-Phase - immunology
Leukemia, Myeloid, Chronic-Phase - therapy
title Abnormal Patterns of Immunoglobulin Heavy Chain Gene DNA Fingerprinting During Chronic Phase Chronic Myeloid Leukemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T21%3A53%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abnormal%20Patterns%20of%20Immunoglobulin%20Heavy%20Chain%20Gene%20DNA%20Fingerprinting%20During%20Chronic%20Phase%20Chronic%20Myeloid%20Leukemia&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Spencer,%20Andrew&rft.date=1999&rft.volume=32&rft.issue=3-4&rft.spage=299&rft.epage=307&rft.pages=299-307&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.3109/10428199909167390&rft_dat=%3Cproquest_infor%3E17218381%3C/proquest_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17218381&rft_id=info:pmid/10037027&rfr_iscdi=true